Literature DB >> 11567963

Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies.

A C Poon1, G Geerling, J K Dart, G E Fraenkel, J T Daniels.   

Abstract

BACKGROUND/AIMS: Autologous serum drops have been reported to be beneficial in keratoconjunctivitis sicca (KCS) and persistent epithelial defects (PED). A clinical pilot study was carried out to examine these potential uses and in vitro toxicity testing on corneal epithelial cell cultures was performed to compare the effect of serum drops with unpreserved hypromellose (hydroxypropylmethylcellulose 0.3%).
METHODS: Patients with KCS and PED, unresponsive to conventional treatment were recruited. Patients were examined before treatment, at 1 and 2 weeks after initiation, and then 2 weekly until treatment ceased. Symptoms were assessed at each visit. Clinical examination included Schirmer's test without anaesthesia, rose bengal staining, and fluorescein staining. Epithelial defects were measured with the slit beam. In the laboratory, cultured human corneal epithelial cells were exposed to serum drops and hypromellose, and their viability evaluated with fluorescent viability staining (Calcein AM ethidium homodimer) and an ATP assay.
RESULTS: Autologous serum was used in 15 eyes of 13 patients with PED and 11 eyes of nine patients with KCS. In two patients serum drops were started after penetrating keratoplasty (PK). The PKs were performed for perforations secondary to PEDs. Of the 15 eyes with PED, nine healed at a mean of 29 days and six failed. The mean duration of PED before the use of serum drops was 48.2 days. Of the 11 eyes with KCS, six had improved subjective scores and fluorescein scores, and five had improved rose bengal scores after the use of serum drops. For the two patients who used serum eyedrops post-PK, there was a stable and intact epithelium at 1 week. Cessation of serum drops during the postoperative period led to deterioration in the subjective and objective scores in both patients. One developed a PED that responded to reinstitution of serum drops. The morphology and ATP levels of cultured epithelial cells exposed to serum were better maintained than those exposed to hypromellose.
CONCLUSION: Autologous serum drops are useful for PED and KCS. This effect may be related to a number of active factors in serum including growth factors, fibronectin, vitamin A, and anti-proteases. In vitro toxicity testing demonstrated that serum drops have reduced toxicity compared with unpreserved hypromellose. Currently regulatory restrictions in the UK have prevented the establishment of a prospective randomised controlled trial examining the efficacy of autologous serum drops for the management of this group of ocular surface disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567963      PMCID: PMC1723716          DOI: 10.1136/bjo.85.10.1188

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  33 in total

1.  A new microcellular cytotoxicity test based on calcein AM release.

Authors:  X M Wang; P I Terasaki; G W Rankin; D Chia; H P Zhong; S Hardy
Journal:  Hum Immunol       Date:  1993-08       Impact factor: 2.850

Review 2.  Growth factors as survival factors: regulation of apoptosis.

Authors:  M K Collins; G R Perkins; G Rodriguez-Tarduchy; M A Nieto; A López-Rivas
Journal:  Bioessays       Date:  1994-02       Impact factor: 4.345

3.  Evaluation of a physiological tear substitute in patients with keratoconjunctivitis sicca.

Authors:  J D Nelson; M M Drake; J T Brewer; M Tuley
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

Review 4.  Evaluation of effects of a physiologic artificial tear on the corneal epithelial barrier: electrical resistance and carboxyfluorescein permeability.

Authors:  J L Ubels; K K Williams; D Lopez Bernal; H F Edelhauser
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

5.  Treatment of persistent corneal epithelial defect by autologous serum application.

Authors:  K Tsubota; E Goto; S Shimmura; J Shimazaki
Journal:  Ophthalmology       Date:  1999-10       Impact factor: 12.079

6.  Topical fibronectin ophthalmic solution in the treatment of persistent defects of the corneal epithelium. Chiron Vision Fibronectin Study Group.

Authors:  J F Gordon; P Johnson; D C Musch
Journal:  Am J Ophthalmol       Date:  1995-03       Impact factor: 5.258

7.  Epidermal growth factor in the topical treatment of traumatic corneal ulcers.

Authors:  C Scardovi; G P De Felice; A Gazzaniga
Journal:  Ophthalmologica       Date:  1993       Impact factor: 3.250

8.  Toxicity of antibiotics and antifungals on cultured human corneal cells: effect of mixing, exposure and concentration.

Authors:  M Berry; A Gurung; D L Easty
Journal:  Eye (Lond)       Date:  1995       Impact factor: 3.775

9.  Calcium: a crucial consideration in serum-free keratinocyte culture.

Authors:  J T Daniels; I R Harris; J N Kearney; E Ingham
Journal:  Exp Dermatol       Date:  1995-08       Impact factor: 3.960

10.  First-order toxicity assays for eye irritation using cell lines: parameters that affect in vitro evaluation.

Authors:  A S Pasternak; W M Miller
Journal:  Fundam Appl Toxicol       Date:  1995-05
View more
  59 in total

1.  Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects.

Authors:  R B Vajpayee; N Mukerji; R Tandon; N Sharma; R M Pandey; N R Biswas; N Malhotra; S A Melki
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

2.  Role of autologous serum in persistent epithelial defects.

Authors:  N Mukerji; R Sinha; R B Vajpayee
Journal:  Br J Ophthalmol       Date:  2002-07       Impact factor: 4.638

3.  The treatment of dry eyes.

Authors:  J P Whitcher
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

4.  [Epitheliotrophic capacity of serum and plasma eyedrops. Influence of centrifugation].

Authors:  P Herminghaus; G Geerling; D Hartwig; T Wedel; L Dibbelt
Journal:  Ophthalmologe       Date:  2004-10       Impact factor: 1.059

5.  Fingerprick autologous blood for dry eyes and persistent epithelial defects.

Authors:  J Wawrzynski; H Mukherjee; J Moore; J Smith; I Reekie; A Patel; B Kumar; C Illingworth; S Shah; D Tole; A Sharma
Journal:  Eye (Lond)       Date:  2015-12-18       Impact factor: 3.775

6.  Pathophysiology of Corneal Scarring in Persistent Epithelial Defects After PRK and Other Corneal Injuries.

Authors:  Steven E Wilson; Carla S Medeiros; Marcony R Santhiago
Journal:  J Refract Surg       Date:  2018-01-01       Impact factor: 3.573

7.  An optimised protocol for the production of autologous serum eyedrops.

Authors:  L Liu; D Hartwig; S Harloff; P Herminghaus; T Wedel; G Geerling
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

8.  Amniotic membrane transplantation for ocular disease: a review of the first 233 cases from the UK user group.

Authors:  Valerie P J Saw; Darwin Minassian; John K G Dart; Andrew Ramsay; Hugo Henderson; Stefan Poniatowski; Ruth M Warwick; Suzanne Cabral
Journal:  Br J Ophthalmol       Date:  2007-02-21       Impact factor: 4.638

9.  Toxic keratopathy related to antiseptics in nonocular surgery.

Authors:  Mei-Chi Tsui; Jen-Yu Liu; Hsiao-Sang Chu; Wei-Li Chen
Journal:  Taiwan J Ophthalmol       Date:  2021-04-27

Review 10.  Autologous serum eye drops for ocular surface disorders.

Authors:  G Geerling; S Maclennan; D Hartwig
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.